Sofwave Medical Aesthetics Secures Chinese Market Approval for Flagship Product

Medical aesthetics company Sofwave has received approval from China's National Medical Products Administration (NMPA) to market and sell its flagship product for wrinkle treatment, skin rejuvenation, and firming. This approval is the crucial first step for the company to enter the Chinese market, where it has partnered with Chinese firm HTDK since 2022 to serve as the exclusive distributor for three years, commencing with regulatory clearance.

The cleared Sofwave system is approved for improving wrinkles in the mid and lower face for individuals aged 22 and above in China. This expansion into the world's second-most populous country, with approximately 1.4 billion people, is a key strategic move for Sofwave. The non-invasive and minimally invasive procedures market in China was valued at around $21 billion in 2023, making it a primary target market for the company.

Sofwave's flagship product, SofwaveTM, utilizes ultrasound technology for non-invasive treatments of facial and neck skin, including lifting eyebrows, tightening sagging skin under the chin, and improving facial wrinkles. In the United States, the company's main market, its device also has FDA approval for treating acne scars and improving the appearance of cellulite and loose skin on the upper arms.

The company, headquartered in Yokneam and founded by Chairman Dr. Shimon Eckhouse, who holds a 23.5% stake, reported record revenues of $30 million and a 67% increase in net profit to $2.5 million in the second quarter of 2026. This marked the fifth consecutive quarter of profitability. North America remains its primary market, accounting for 54% of its $88 million in total revenues in 2025, while East Asia contributed 33% ($28.5 million), with South Korea, Japan, and Australia being key markets.

Sofwave, established in 2015 and publicly traded on the Tel Aviv Stock Exchange since May 2021, has experienced significant stock fluctuations. After an initial IPO at a valuation of 800 million shekels, the company's market value dropped to a low of 239 million shekels in June 2023. However, improved revenues and stabilizing R&D expenses led to a recovery, with its market cap exceeding 1 billion shekels by August 2023. A surge in interest, partly attributed to influencer Kim Kardashian endorsing the company's treatments, pushed its valuation to a record 1.7 billion shekels in May, though it has since declined by 37%. This recent decline coincides with the company's decision to withdraw its Nasdaq dual listing plans and a financial penalty imposed on Chairman Eckhouse by the Israel Securities Authority for misleading disclosures related to another company he chairs.